,Canonical_Smiles,drug_name,drug_type,Label
0,CSc1ccc2c(c1)N(CC[C@H]1CCCCN1C)c1ccccc1S2,thioridazine_R,2E1-Substrate,negative
1,C[C@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1,Bupropion,2D6-Inhibitor,positive
2,Cc1ccc2c(=O)c3cccc(CC(=O)O)c3oc2c1C,DMXAA,1A2-Substrate,negative
3,COc1ccc(C(c2ccc(O)c(O)c2)C(Cl)(Cl)Cl)cc1,catechol_methoxychlor,2D6-Substrate,negative
4,N=C(N)NC[C@H]1COc2ccccc2O1,Guanoxan,2D6-Substrate,negative
5,Cc1nc[nH]c1CN1CCc2c(c3ccccc3n2C)C1=O,Alosetron,2E1-Inhibitor,negative
6,CNC(=O)Oc1cc(C)c(SC)c(C)c1,Methiocarb,2D6-Substrate,negative
7,CCCN(CCC)N=O,NN_dipropyl_nitrosoamine,2E1-Substrate,negative
8,CCNCc1cc(=O)oc2cc(OC)ccc12,EMAMC,2D6-Substrate,negative
9,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1,Cefalexin,Multidrug_and_toxin_extrusion_protein_1-Substrate,negative
10,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3[C@@H](CC)C[C@@]21C,org_4060,3A4-Substrate,negative
11,NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O,Chlorothiazide,Solute_carrier_family_22_member_8-Substrate,negative
12,O=c1c(O)c(-c2ccccc2)oc2cc(O)cc(O)c12,galangin,2C9-Substrate,negative
13,CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1,Atenolol,3A4-Substrate,negative
14,C[C@H](COc1ccccc1)N(CCCl)Cc1ccccc1,Phenoxybenzamine,3A4-Substrate,negative
15,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,Cyproterone,19A-Inhibitor,negative
16,CO[C@@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,Artemether,2D6-Substrate,negative
17,CC(Nc1cc(-c2[nH]c(S(C)=O)nc2-c2ccc(F)cc2)ccn1)c1ccccc1,ML_3603,2D6-Substrate,negative
18,CCC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12,Hydroquinidine,2D6-Inhibitor,positive
19,C/C=C/C,trans_2_butene,2E1-Substrate,negative
20,N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,Melphalan,GST-Substrate,negative
21,C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](C[C@H]2C=Nc3ccccc32)NC[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN3CCN(CC(=O)O)CC(=O)O[In](OC(=O)C3)OC(=O)C2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,Indium (111In) Pentetic Acid,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
22,Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C,Riboflavin (vit B2),ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
23,CC[S@@](=O)c1c(C#N)nn(-c2c(Cl)cc(C(F)(F)F)cc2Cl)c1N,ethiprole,3A4-Substrate,negative
24,O=S1OCC2C(CO1)C1(Cl)C(Cl)=C(Cl)C2(Cl)C1(Cl)Cl,endosulfan,2C19-Substrate,negative
25,CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,Itraconazole,2D6-Inhibitor,positive
26,CNCC[C@@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Fluoxetine,2D6-Inhibitor,positive
27,CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1,Talinolol,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
28,CCOc1ccc2c(C(F)(F)F)cc(=O)oc2c1,7_ethoxy_4_trifluoro_methyl_coumarin,2E1-Substrate,negative
29,O=C(O)c1cc(N=Nc2ccc(O)c(C(=O)O)c2)ccc1O,Olsalazine,Methyltransferase-Inhibitor,negative
30,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1,barnidipine,2D6-Substrate,negative
31,C[C@H](N)[C@H](O)c1cccc(O)c1,Metaraminol,Sodium_dependent_noradrenaline_transporter-Substrate,negative
32,CC(=O)N=c1sc(S(N)(=O)=O)nn1C,Methazolamide,2D6-Inhibitor,positive
33,O=C(O)CCCC[C@@H]1CCSS1,Tioctic Acid,GST-Inducer,negative
34,O=C1CC(=O)N(c2ccccc2)c2cc(Cl)ccc2N1,N_desmethyl_clobazapam,2C19-Substrate,negative
35,OO,Hydrogen Peroxide,GST-Inhibitor,negative
36,CCN[C@H](C)Cc1ccc2c(c1)OCO2,MDE_R,2E1-Substrate,negative
37,COC(=O)[C@H](c1ccccc1Cl)N1CCC2SC(=O)C=C2C1,2_oxo_clopidogrel,2D6-Substrate,negative
38,CN1CCN(C(c2ccccc2)c2ccccc2)CC1,Cyclizine,2C9-Inhibitor,negative
39,NC[C@@H](O)c1ccc(O)c(O)c1,Norepinephrine,19A-Inhibitor,negative
40,CNC(=S)Oc1cc(C)c(SC)c(C)c1,methiocarb,2D6-Substrate,negative
41,OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1,Opipramol,2D6-Substrate,negative
42,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,Meloxicam,-,negative
43,CC(C)(N)Cc1ccccc1,Phentermine,2D6-Inhibitor,positive
44,Cc1ncc2c(c1O)CO[C@@H]2c1ccc(Cl)cc1,Cicletanine,UGT-Substrate,negative
45,C[C@@H](N)Cc1ccccc1,Amfetamine,2D6-Inhibitor,positive
46,C=C(C)[C@@H]1CC=C(C)CC1,limonene_S,2C19-Substrate,negative
47,CC(=O)C[C@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,Warfarin,CP2CI-Substrate,negative
48,O=O,Oxygen,Solute_carrier_family_12_member_2-Inducer,negative
49,CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,Clomifene,19A-Inhibitor,negative
50,NC(Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,Liothyronine,-,negative
51,CS(C)=O,Dimethyl Sulfoxide,2D6-Inhibitor,positive
52,c1ccc([C@H]2CN3CCSC3=N2)cc1,Levamisole,GST-Inducer,negative
53,COc1ccc2c(c1)Oc1cc(O)ccc1C21OC(=O)c2ccccc21,3_O_methyl_fluorescein,2C19-Substrate,negative
54,CC(C)[C@]12CC(=O)[C@@H](C)[C@H]1C2,beta_thujone,3A4-Substrate,negative
55,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,Mitoxantrone,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
56,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,Amodiaquine,2D6-Inhibitor,positive
57,O=[S@](Cc1cc(OCC2CC2)ccn1)c1nc2ccc(F)cc2[nH]1,H_259_31_R,2C19-Substrate,negative
58,CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12,Eletriptan,2D6-Substrate,negative
59,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1,sibutramine,2C19-Substrate,negative
60,NCC(=O)O,Glycine,GST-Inducer,negative
61,CC(=O)OCC[N+](C)(C)C,Acetylcholin,Methyltransferase-Inducer,negative
62,C[C@@H](CCc1ccccc1)NC[C@H](O)c1ccc(O)c(C(N)=O)c1,Labetalol,2D6-Inhibitor,positive
63,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,Sildenafil,2D6-Inhibitor,positive
64,CC(=O)Nc1ccc(OC(C)C)cc1,O_isopropyl_acetaminophen,1A2-Substrate,negative
65,COc1cc2c(cc1OC)C(=O)[C@H](CC1CCN(Cc3ccccc3)CC1)C2,Donepezil,2D6-Substrate,negative
66,CCN(CC)c1cc(C)nc2ncnn12,Trapidil,-,negative
67,C[C@@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@H]2O,Estradiol,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
68,CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C=O)C[C@@H]21,11_oxo_delta_8_tetrahydro_cannabinol,2D6-Substrate,negative
69,O=C1C=C2CN(C(C(=O)C3CC3)c3ccccc3F)CCC2S1,R_95913,2D6-Substrate,negative
70,C=CCc1cc(OC)c2c(c1)OCO2,myristicin,1A2-Substrate,negative
71,CC/C=C\Cn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_11,3A4-Substrate,negative
72,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,Rutoside,2D6-Inhibitor,positive
73,CC(C)[C@H](N)C(=O)OC[C@H](CO)OCn1cnc2c(=O)nc(N)[nH]c21,Valganciclovir,Solute_carrier_family_15_member_2-Inhibitor,negative
74,CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@H](c2ccccc2)NC(=O)[C@H]2CC(=O)[C@H](CS[C@@H]3CN4CCC3CC4)CN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@@H]2CCCN2C1=O,Quinupristin/dalfopristin,3A4-Inhibitor,negative
75,C[C@]12C[C@@H]3C[C@](C)(C1)C[C@@](N)(C3)C2,Memantine,2D6-Inhibitor,positive
76,Nc1nc2c(ncn2COCCO)c(=O)[nH]1,Aciclovir,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
77,NC(N)=NN=Cc1c(Cl)cccc1Cl,Guanabenz,-,negative
78,CC(=O)NCC1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,Linezolid,-,negative
79,CC(C)(CO)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,w_OH_finasteride,3A4-Substrate,negative
80,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1c1cccc([N+](=O)[O-])c1,Nitrendipine,P450_HFLA-Substrate,negative
81,COC1=C[C@@H](C)[C@@H]2C[C@@H]3OC(=O)C[C@H]4C(C)=C(OC)C(=O)[C@H]([C@@]2(C)C1=O)[C@]34C,Quassia,1A1-Inhibitor,negative
82,FC(F)OC(F)(F)C(F)Cl,enflurane,2E1-Substrate,negative
83,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,Simvastatin,2D6-Inhibitor,positive
84,CCCC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2CO[P@@](=O)(O)O[C@H]2[C@H]1OC(=O)CCC,Bucladesine,19A-Inducer,negative
85,CCCCCNC(=N)NN=Cc1c[nH]c2ccc(CO)cc12,Tegaserod,2D6-Inhibitor,positive
86,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,Etoricoxib,2D6-Inhibitor,positive
87,O=C(CCCN1CCC(O)(c2cccc(C(F)(F)F)c2)CC1)c1ccc(F)cc1,Trifluperidol,2D6-Substrate,negative
88,CCNc1nc(Cl)nc(NC(C)C)n1,atrazine,2E1-Substrate,negative
89,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1,Chlorambucil,GST-Inducer,negative
90,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@@H]1c1cccc([N+](=O)[O-])c1,Barnidipine,2D6-Inhibitor,positive
91,CC1=C(C)C(=O)C([C@H](CCCCCC(=O)O)c2ccccc2)=C(C)C1=O,Seratrodast,2D6-Inhibitor,positive
92,COc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,3_methylether_estradiol,2C19-Substrate,negative
93,CN(C)CCOc1ccc(C(=C(CCCl)c2ccccc2)c2ccccc2)cc1,Toremifene,-,negative
94,Nc1nc(=O)c(Br)c(-c2ccccc2)[nH]1,bropirimine,1A2-Substrate,negative
95,O=C1OC2(c3ccc(OCc4ccccc4)cc3Oc3cc(OCc4ccccc4)ccc32)c2ccccc21,dibenzyl_fluorescein,2D6-Substrate,negative
96,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,Duloxetine,2D6-Inhibitor,positive
97,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,Naproxen,SUL-Inhibitor,negative
98,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,bortezomib,2D6-Substrate,negative
99,CCCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_5,3A4-Substrate,negative
100,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,Resiquimod,-,negative
101,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,Ethinylestradiol,P450_HFLA-Substrate,negative
102,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,Metandienone,3A4-Substrate,negative
103,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C=O)C(C)(C)CCC1,9_cis_retinal,2C19-Substrate,negative
104,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,17_beta_estradiol,2C9-Substrate,negative
105,Cc1ncc([N+](=O)[O-])n1CCO,Metronidazole,-,negative
106,COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c[nH]c2c1,BPR_0L075,2E1-Substrate,negative
107,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H]1CSSCCC(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,Desmopressin,Solute_carrier_family_12_member_1-Inducer,negative
108,C=C1CC[C@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,Colecalciferol,2D6-Inhibitor,positive
109,COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,Tramadol,2D6-Inhibitor,positive
110,CN(C)N=Nc1[nH]cnc1C(N)=O,Dacarbazine,2E1-Substrate,negative
111,NCC1(CC(=O)O)CCCCC1,Gabapentin,GST-Inducer,negative
112,CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@@H]2OC(=CCCCC(=O)O)C[C@@H]21,Epoprostenol,2C9-Substrate,negative
113,CS(=O)(=O)OCCCCOS(C)(=O)=O,Busulfan,GST-Substrate,negative
114,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,Palonosetron,2D6-Substrate,negative
115,Cc1cc2c3ccccc3ccc2c2ccccc12,6_methylchrysene,2E1-Substrate,negative
116,CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CCC12C,Chenodeoxycholic acid,-,negative
117,CCN(CC)C(=O)C1(c2ccccc2)CC1CN,Milnacipran,-,negative
118,C=CC(=C)C,isoprene,2E1-Substrate,negative
119,C[C@H](c1cc2ccccc2s1)N(O)C(N)=O,zileuton_R,2E1-Substrate,negative
120,Cc1ccnc(NC(=O)[C@H](C)c2cccc(C(=O)c3ccccc3)c2)c1,Oxatomide,2D6-Inhibitor,positive
121,CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1,Carbinoxamine,2D6-Inhibitor,positive
122,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)C(=O)C1=O,Cefoperazone,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
123,COCCCOc1ccnc(CSc2nc3ccccc3[nH]2)c1C,rabeprazole_thioether,2E1-Substrate,negative
124,CC1O[C@@]2(CS1)CN1CCC2CC1,Cevimeline,2D6-Substrate,negative
125,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,Timolol,2D6-Inhibitor,positive
126,CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,Ebastine,-,negative
127,CC(=O)Oc1ccccc1C(=O)O,Acetylsalicylic Acid,GST-Inducer,negative
128,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C,Dextropropoxyphene,2D6-Inhibitor,positive
129,CC(c1cc2ccccc2s1)N(O)C(N)=O,Zileuton,2D6-Inhibitor,positive
130,Cc1cc(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)c1Br,Technetium (99mTc) Mebrofenin,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
131,CCC(c1ccc(O)c(F)c1)C(C)c1ccc(O)c(F)c1,Bifluranol,-,negative
132,CN1CCN(CCCCN2C(=O)CN(N=Cc3ccc(-c4ccc(Cl)cc4)o3)C2=O)CC1,Azimilide,-,negative
133,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,Chlorpromazine,2D6-Inhibitor,positive
134,CCCN1CCC[C@@H](c2cccc(S(C)(=O)=O)c2)C1,OSU_6162,2D6-Substrate,negative
135,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O,Benzylpenicillin,Canalicular_multispecific_organic_anion_transporter_1-Inducer,negative
136,O=[P@@]1(N(CCCl)CCCl)OCCCN1CCCl,Trofosfamide,-,negative
137,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,Diflunisal,UGT-Substrate,negative
138,C[N+](C)([O-])CCCN1c2ccccc2CCc2ccccc21,Imipramine Oxide,1A2-Substrate,negative
139,CCOc1ccc2nc3ccc(=O)cc-3oc2c1,7_ethoxy_resorufin,1A2-Substrate,negative
140,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,Bromocriptine,-,negative
141,O=C(c1cccs1)c1ccc(O)c(Cl)c1Cl,tienilic_acid_deriv_1,2C9-Substrate,negative
142,COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,Trabectedin,2E1-Substrate,negative
143,CCC1(c2ccccc2)C(=O)NCNC1=O,Primidone,-,negative
144,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,Telmisartan,-,negative
145,c1ccc(C2(N3CCCCC3)CCCCC2)cc1,Phencyclidine,-,negative
146,COc1ccccc1OCCNC[C@H](O)COc1cccc2[nH]c3ccccc3c12,carvedilol_S,2D6-Substrate,negative
147,N#Cc1nn(-c2c(Cl)cc(C(F)(F)F)cc2Cl)c(N)c1[S@](=O)C(F)(F)F,fipronil,2C19-Substrate,negative
148,CCCCCC,hexane,2E1-Substrate,negative
149,CN[C@H](C)Cc1ccccc1,methamphetamine_R,2D6-Substrate,negative
150,CC[C@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,Phenprocoumon,-,negative
151,O[C@@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1,Nebivolol,2D6-Substrate,negative
152,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,retinol,2D6-Substrate,negative
153,CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,Pyrimethamine,2D6-Inhibitor,positive
154,CNCC[C@@H](Oc1ccccc1C)c1ccccc1,Atomoxetine,2D6-Inhibitor,positive
155,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,Remoxipride,2D6-Substrate,negative
156,CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,Sulpiride,-,negative
157,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,Clofibrate,4A11-Substrate,negative
158,O=[P@@]1(N(CCCl)CCCl)NCCCO1,Cyclophosphamide,CP2CI-Substrate,negative
159,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,Oxymetazoline,UGT-Substrate,negative
160,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,pregnenolone,2D6-Substrate,negative
161,S=P(N1CC1)(N1CC1)N1CC1,Thiotepa,GST-Substrate,negative
162,N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,Chlorhexidine,Methyltransferase-Inhibitor,negative
163,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@@H]1c1cccc([N+](=O)[O-])c1,Nimodipine,-,negative
164,O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O,Niclosamide,2D6-Inhibitor,positive
165,COc1ccc(C(c2ccc(OC)cc2)C(Cl)(Cl)Cl)cc1,methoxychlor,2C19-Substrate,negative
166,Cc1ccc(O)c([C@@H](CCN(C(C)C)C(C)C)c2ccccc2)c1,Tolterodine,2D6-Substrate,negative
167,CS(=O)(=O)OC[C@H](O)[C@H](O)COS(C)(=O)=O,Treosulfan,1A2-Inhibitor,negative
168,CCNC(=O)[C@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H]1CCC(=O)N1,Buserelin,19A-Inducer,negative
169,O=C1c2ccccc2C(=O)c2ccccc21,Anthraquinone,-,negative
170,C=CCC1(C(C)C)C(=O)NC(=O)NC1=O,Aprobarbital,2B6-Inducer,negative
171,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)C3=CCC=CC3)[C@H]2SC1,Cefradine,Solute_carrier_family_15_member_1-Inhibitor,negative
172,CC(C)(C)NCC(O)COc1ccccc1C1CCCC1,Penbutolol,2D6-Substrate,negative
173,COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1,Formoterol,2D6-Substrate,negative
174,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,clarithromycin,3A4-Substrate,negative
175,COC1=CC(=O)OC1C(O)c1ccccc1Cl,Losigamone,-,negative
176,CN1CCCCC1CCN1c2ccccc2Sc2ccc(S(C)=O)cc21,mesoridazine,2D6-Substrate,negative
177,c1ccc(COc2ccc3cccnc3c2)cc1,7_benzyloxy_quinoline,1A2-Substrate,negative
178,CC(=O)c1cc2ccccc2s1,2_acetylbenzothiophene,2E1-Substrate,negative
179,CN(C)N/N=C1\N=CN=C1C(N)=O,dacarbazine,2E1-Substrate,negative
180,Oc1ccccc1,Phenol,2E1-Substrate,negative
181,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,Parecoxib,2D6-Inhibitor,positive
182,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,cinnarizine,2D6-Substrate,negative
183,C[C@H](CN(C)C)CN1c2ccccc2Sc2ccc(C#N)cc21,Cyamemazine,2C9-Substrate,negative
184,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D2,3A4-Substrate,negative
185,CCCCNCc1cc(=O)oc2cc(OC)ccc12,BMAMC,2D6-Substrate,negative
186,CN[C@@H](C)Cc1ccccc1,Metamfetamine,2D6-Inhibitor,positive
187,O=C1N(c2ccccc2)c2ccccc2C1(Cc1ccncc1)Cc1ccncc1,Linopirdine,P450_HFLA-Substrate,negative
188,CCC[C@@](C)(COC(N)=O)COC(=O)NC(C)C,Carisoprodol,-,negative
189,CC(C(=O)c1ccc2c(c1)OCO2)N1CCCC1,MDPPP,2D6-Substrate,negative
190,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21,Emetine,2D6-Inhibitor,positive
191,Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,Cefazolin,Solute_carrier_family_22_member_6-Substrate,negative
192,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,Colchicine,2E1-Inducer,negative
193,CN[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H]([C@@H](C)NC)CC[C@@H]3N)[C@@H]2O)OC[C@]1(C)O,Gentamicin,Canalicular_multispecific_organic_anion_transporter_1-Inducer,negative
194,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,Kanamycin,Solute_carrier_family_12_member_2-Inhibitor,negative
195,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,9_cis_retinoic_acid,2C9-Substrate,negative
196,CC1=CC(=O)C=C2CCC3C4CCC(=O)C4(C)CCC3C12C,Atamestane,-,negative
197,Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1,Tolcapone,Methyltransferase-Inhibitor,negative
198,COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,muraglitazar,2E1-Substrate,negative
199,CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,Roquinimex,-,negative
200,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12,Abiraterone,-,negative
201,CCOc1ccc(NC(C)=O)cc1,Phenacetin,2E1-Substrate,negative
202,Cn1c(N)nc2c3cccnc3ccc21,2_amino_3_methylimidazo_4_5_f_quinoline,1A2-Substrate,negative
203,OCCc1ccccc1Nc1c(Cl)cccc1Cl,diclofenac_deriv_2,2C19-Substrate,negative
204,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@H]1c1ccccc1Cl,Amlodipine,2D6-Inhibitor,positive
205,O=C(CS(=O)Cc1ccco1)NCC=CCOc1cc(CN2CCCCC2)ccn1,Lafutidine,2C19-Inhibitor,negative
206,CCNc1ncn(Cc2ccc(OC)c(OC3CCCC3)c2)c2nc(C(C)C)nc1-2,V_11294,2D6-Substrate,negative
207,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Clopidogrel,-,negative
208,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@@H]13,Eplerenone,P450_HFLA-Substrate,negative
209,CCOC(=O)C1(c2ccccc2)CCN(C)CC1,meperidine,2D6-Substrate,negative
210,CCCCCCOc1ccc2ccc(=O)oc2c1,7_hexoxy_coumarin,3A4-Substrate,negative
211,CCCCCCCCCCCCCCCC(=O)O,palmitic_acid,2E1-Substrate,negative
212,CC(=O)[C@H]1CC[C@H]2[C@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@@H]3[C@H](O)C[C@]12C,Medrysone,2D6-Inhibitor,positive
213,CCC[C@@H](C)C1(CC)C(=O)NC(=O)NC1=O,Pentobarbital,-,negative
214,CC(C)n1c(C=C[C@H](O)C[C@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,Fluvastatin,2D6-Inhibitor,positive
215,CC(O)(CC(=O)O)CC(=O)O,Meglutol,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
216,CCC[C@@H](C)[C@@]1(CC)C(=O)N=C(S)NC1=O,Thiopental,2E1-Inhibitor,negative
217,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,Aceclofenac,-,negative
218,CC(C)N=C(N)N=C(N)Nc1ccc(Cl)c(Cl)c1,Chlorproguanil,-,negative
219,CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,Neostigmine,P450_HFLA-Inhibitor,negative
220,NC(=O)N1c2ccccc2CC(=O)c2ccccc21,Oxcarbazepine,-,negative
221,Cc1cc2ccccc2c2ccc3ccccc3c12,5_methylchrysene,2E1-Substrate,negative
222,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,Erlotinib,UGT-Inhibitor,negative
223,COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12,Carvedilol,2E1-Substrate,negative
224,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,Rifaximin,3A4-Inducer,negative
225,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@H]1OC,Cisapride,2D6-Inhibitor,positive
226,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,montelukast,2D6-Substrate,negative
227,CCCO,Propanol,-,negative
228,O=C([O-])O,Sodium Bicarbonate,Electroneutral_sodium_bicarbonate_exchanger_1-Substrate,negative
